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ABSTRACT 
Malaria is a disease that has affected people throughout the world for centuries and 
is still responsible for over 200 million clinical cases per year. While a number of 
developed countries have eradicated the disease, its prevalence in tropical regions poses a 
significant global health challenge. The disease is caused by the Plasmodium genus, an 
obligate, intracellular parasite that is carried by the female Anopheles mosquito. While 
there are effective antimalarial drugs in clinical use, Plasmodium’s resilient nature has 
allowed it to develop resistance to multiple drugs. This fact makes it imperative to seek out 
novel drugs to combat resistant strains. Combination therapies are one effective way to 
treat malaria and prevent the incidence of drug resistance. The most commonly used class 
of combination therapy is the Artemisinin Based Combination Therapy. However, there is 
evidence that artemisinin resistance could be occurring in the field. 
In this study, new combinations were tested between the standard antimalarial 
drugs namely, chloroquine (CQ) and artemisinin (ART) along with the experimental 
antimalarial drugs namely an artemisinin dimer oxime (DIOX) and NPC1161B (NPC) (an 
8-aminoquinoline). The combinations were tested in vitro using the SYBR Green-I based 
fluorescence assay with a drug-resistant W2 strain of Plasmodium falciparum (P.f.) in a 
checkerboard assay template. Resistance of Pf (W2) towards CQ was confirmed. Both 
DIOX and NPC showed partial antagonistic effect on the antimalarial action of CQ and 
artemisinin. Further in vivo evaluation of these combinations in rodent malarial models 
would be important for confirmation of these results.   
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Chapter I: Background and Significance 
1.1  Introduction 
 Malaria is a disease that has affected the people of the world for thousands of years. 
According to the Center for Disease Control (CDC), 3.2 billion people live in areas that 
are at risk of transmission, and in 2016, estimated 216 million clinical cases of malaria 
were reported (WHO, 2017). This incidence of infection resulted in nearly 445,000 
fatalities. Of the infected population, the most vulnerable are young children, pregnant 
women and travelers from non-endemic regions (Impact of Malaria, 2017). As shown in 
the global malaria distribution map (Figure 1), infections are prominent in tropical regions, 
especially in India and Sub-Saharan Africa.  
 
Figure 1: CDC map representing the global distribution of human Malaria cases from 
the Center for Disease control 
 Limited numbers of drugs and no viable vaccines to treat or prevent the disease 
make malaria a prominent global health challenge. Additionally, increasing resistance of 
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the malaria parasite to commonly used drugs creates a sense of extreme urgency to discover 
and incorporate new antimalarial drugs that are both cost-effective and easily administered 
1.2 History 
 Malaria has been with humans throughout history, but it was not until the many 
technological advances of the past century that medicine’s understanding of the origin, 
transmission and life cycle of the disease could be understood. Although many people 
contracted malaria and were familiar with its symptoms, the true cause of the disease was 
not discovered until Alphonse Laveran, Ronald Ross, Battista Grassi, and their colleagues 
identified the malaria parasite in the 1880’s and 1890’s (Meshnick and Dobson, 2001). 
Additionally, Ross was awarded the Nobel Prize in 1902 for demonstrating that the malaria 
parasite is transmitted to humans through a mosquito vector (The History of Malaria 2017). 
This discovery allowed scientists to better understand how to combat the symptoms and 
spread of malaria.  
 Like many early drugs, the first antimalarial drugs, namely quinine and artemisinin, 
were discovered hundreds of years before the disease was understood on a physiological 
and biochemical level. The earliest remedies for malaria came from the bark of the 
cinchona tree and the qinghao plant; these remedies were later synthetically separated as 
quinine and artemisinin respectively (Meshnick and Dobson 2001). During the conquest of 
the new world and the spread of imperialism by Europeans, the interest for developing 
effective antimalarial drugs reached new heights. However, it was not until the twentieth 
century that resistance to malaria drugs became evident. This had proved to be a major 
challenge that has continued to this day creating a great need for new antimalarial drugs.  
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1.3 The Parasite  
Members of the Plasmodium genus are responsible for the symptoms of malaria. 
Plasmodium parasites are obligate intracellular protozoan parasites that have a complex 
life cycle. This includes time spent in both humans and female the Anopheles mosquitos, 
malaria’s primary vector of transmission.  There are four species of Plasmodium that cause 
the disease in humans: P. falciparum, P. vivax, P. ovale, and P. malariae (WHO 2017). P. 
falciparum, which is the species used in the experiments presented in this thesis, by far 
causes the most clinical cases of malaria worldwide resulting in over 200 million clinical 
cases of malaria per year (Lui et al., 2016).  Because P. falciparum is the most virulent 
species it naturally draws the most attention for research, but the other species are just as 
dangerous. P. vivax is estimated to cause anywhere from 35 million to 80 million cases of 
malaria per year, and these infections, like P. falciparum, are capable of causing morbid 
disease states that can easily result in fatality (Galinski 2008). Although P. ovale and P. 
malariae can independently infect humans, these species most commonly infect 
opportunistically along with P. falciparum, and additionally, it is much more difficult to 
detect these species by light microscopy techniques (Rutledge et al 2017, Doctor et al. 
2016). Because of these facts, there is less research and discovery focused on these species 
because of the pressing need to discover new drugs to combat drug resistant strains of P. 
falciparum.   
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1.4 Life Cycle 
 The Plasmodium parasites have a complicated life cycle that includes a period in 
both humans and female Anopheles mosquitos. The parasites also have both an asexual and 
sexual stage of growth and reproduction throughout their life cycle. Figure 2 provides an 
overview of this complicated life cycle. 
 
 
Figure 2: Life cycle of Plasmodium from the Center for Disease Control 
 There are three primary stages in the parasite’s life cycle: The Exo-Erythrocytic 
Cycle, the Erythrocytic Cycle, and the sexual Sporogonic Cycle. The life cycle as depicted 
in Figure 2 begins in the asexual stage when an infected female Anopheles mosquito bites 
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a human and introduces sporozoites into circulation. After arriving in the bloodstream, the 
parasites circulate and are taken up by the liver. Within the liver hepatocytes, the parasites 
enter the schizont stage of development where they multiply rapidly eventually causing 
cell rupture and release of thousands of infectious merozoites into the bloodstream. At this 
stage, P. vivax has the unique ability to remain dormant and replicates in the liver allowing 
for subsequent infection, weeks to even months after initial exposure to the parasite 
(Siciliano, 2015). These merozoites then infect human erythrocytes and subsequently 
progress to the ring stage, and at this point have two available pathways.  
The first pathway involves maturation into a mature trophozoite, which then again 
progresses into many infectious merozoites that continue the erythrocyte infection stage. 
During the Erythrocytic Cycle, the parasite is dependent on human Red Blood Cells 
(RBCs) because it feeds on the Oxygen carrying protein hemoglobin (Miller, 2013). In P. 
falciparum and vivax, this cycle is completed in 43-48 hour intervals causing the observed 
2 day spike in fever and other symptoms associated with the clinical malaria infections 
(Fujioka 1999).  
The second available pathway is the progression to the sexual gametocyte stage of 
the life cycle. A mosquito that is feeding on an infected human can then take up the 
gametocytes. Within the mosquito, the parasite goes through its process of sexual exchange 
of genetic material and multiplies into many sporozoites preparing the parasite for infection 
during the mosquito’s next blood meal. The different stages of the life cycle can be easily 
identified by light microscopy and are presented in Figure 5 in chapter II.  
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1.5 Clinical Presentation 
 While some complications can occur during the liver stage of the infection, the most 
prominent symptoms of malaria occur during the Erythrocytic Cycle. Major symptoms of 
the disease are high fever, sweating, and moderate to severe chills; while headache, 
diarrhea and vomiting may also be present in some cases. These symptoms do not usually 
directly cause fatalities, but they can lead to more serious complications that present in 
severe cases of the infection. Severe complications include: cerebral malaria causing 
swelling of the brain, breathing problems caused by pulmonary edema, liver or kidney 
failure, low blood sugar, and severe anemia resulting from the destruction of erythrocytes 
during the blood stage of infection (Mayo Clinic, 2018). These severe complications are 
very difficult to combat in the poor, rural areas of the tropics and Africa and are responsible 
for malaria’s extremely high mortality rates. 
Because the malaria life cycle and infection is multifaceted and complicated, a 
variety of treatment methods are required to overcome the disease. Management of 
symptoms in severe cases is imperative to survival and can be accomplished through: 
intravenous fluids to combat dehydration due to vomiting and diarrhea, blood transfusion 
to reverse anemia caused by the Erythrocytic Cycle, and dextrose is provided intravenously 
to reverse the effects of low blood sugar (White et al., 2014). There is also a variety of 
antimalarial drugs available that can effectively clear the body of infection. However, these 
drugs are sometimes inaccessible to the populations in need and the parasite can become 
resistant to certain drug therapies. The discussion of antimalarial drugs is presented in the 
following section.  Prevention of the disease is highly recommended and can be 
accomplished through a variety of methods. A popular approach to prevention is the 
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“A.B.C.D.” method: Awareness of risk, Bite avoidance, Compliance with prophylaxis, and 
Diagnosis after fever (Genton, 2012). Awareness education programs help populations to 
avoid bites through the use of bed nets, insect repellent and management of standing water 
sources, which can support mosquito reproduction (Burke 2017). These measures can help 
limit the transmission of the disease, however malaria will nevertheless still be a major 
problem in endemic areas and it is therefore imperative to continue to develop new drugs 
in order to combat the deadly disease.  
 
1.6 Malaria Drug Discovery 
 Because Plasmodium has the potential to adapt and become resistant to antimalarial 
drugs, it is imperative to develop and utilize methods to discover novel drugs in order to 
fight the ever-adapting genome of the parasite. These methods include screening for new 
drug candidates, in vitro and in vivo models to test the efficacy of drugs, and diagnostic 
methods to determine the amount of parasitemia, or relative number of infected RBCs, in 
a model.  
1.6.1 Antimalarial Drugs 
 The first synthetic antimalarial drug discovered was chloroquine, which was 
discovered in 1934. Chloroquine is considered one of the most important drugs in the 
history of infectious disease treatment, and along with the development of DDT, there were 
hopes that the disease could be potentially eradicated from the world (Wellems, 2001). 
While this feat would be monumental, it was determined to only be hope. Like all living 
things, Plasmodium is a resilient parasite and eventually mutated, developing resistance to 
this widely distributed antimalarial. P. falciparum chloriquine resistance was first 
recognized in the 1950’s and has nearly spread across the globe. Additionally, resistance 
8 
 
 
 
in P. vivax was discovered in 1989 and has since spread as well (Baird, 2018). The effects 
of chloroquine resistance were noticeably drastic. Hospital studies conducted in Africa in 
the 1980’s showed a 2-3 times increase, and 6 times in the case of Senegal, increase in 
malaria deaths that could be attributed to the parasite’s development of chloroquine 
resistance (Trape, 2001). The development of chloroquine resistance caused the 
pharmaceutical community to eagerly begin the search for new drugs to combat the disease.  
 Artemisinin was one of the drugs that was discovered in response to the chloroquine 
resistance crisis that occurred in the mid twentieth century. It was isolated in the 1960’s by 
Chinese scientists and in 2006 there was a worldwide demand for nearly 100 million 
artemisinin-based combination therapies (Covello, 2008). The World Health Organization 
switched to this new combination treatment strategy in 2005 and it has proved to be 
effective in saving many lives (Tu, 2011). These treatments are currently regarded as the 
most effective treatments for malaria and are being utilized across the world in malaria 
endemic regions.  
Artemisinin’s primary mechanism of action takes advantage of the parasite’s 
reliance on erythrocyte hemoglobin for nutrients. Normally, the drug has limiting effects 
on humans because it is activated by the heme, which is typically locked away inside the 
hemoglobin of RBCs. However, during the multiplication of malaria parasites within the 
host RBCs, hemoglobin is rapidly digested and free heme is present in infected RBCs; this 
allows artemisinin to become active and enact cytotoxic effects on the parasites (Wang, 
2017). While there have yet to be confirmed cases of artemisinin insensitive strains of 
malaria parasites, there have been observations in the last decade that in some cases of 
malaria are beginning to take longer than normal to clear the parasite with artemisinin-
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combination therapies (Sibley, 2015). This trend suggests that, like chloroquine, malaria 
parasites have the potential to develop resistance to artemisinin and artemisinin-
combination therapy treatments in the coming years. 
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Figure 3: A portfolio of the current antimalarial drugs in each stage of development 
available from Medicines for Malaria Venture 
The Medicines for Malaria Venture (MMV) was established as a Public-Private-
Partnership for antimalarial drug development. MMV has established a network of more 
than 160 partners world-wide, which include the research labs from the academic 
institutions, global health agencies, government organizations and pharmaceutical 
companies. With these partnerships, MMV has established one of the largest antimalarial 
drug discovery portfolios shown in Figure 3. This portfolio includes the candidate’s drugs 
in clinical development especially for medical needs in malaria. This includes the 
medicines for children and pregnant women.    
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1.6.2 Antimalarial Drug Discovery Models 
 The experimental models are important tools for pharmacological drug discovery. 
They provide the necessary tools to test the efficacy and safety of novel drug targets in a 
more controlled and ethical environment. Researches searching for new antimalarial drug 
therapies have both an in vitro and in vivo option for testing the effectiveness of new 
compounds and drug combinations.  
1.6.2.1 In vitro Malaria Model 
 One of the greatest obstacles that early researchers faced was the inability to 
effectively culture the Plasmodium parasite. This forced early research to be primarily 
clinical and made it difficult and potentially unethical to attempt to use new antimalarial 
drugs on human subjects. Currently, the practice of culturing P. falciparum in the 
laboratory is common and is extremely effective for screening potential new drug targets. 
The common protocols to culture P. falciparum use A+ human erythrocytes, specific cell 
culture media, and A+ human serum, which can be replaced with a lipid- rich serum 
albumin fraction. The P. falciparum cultures are maintained in a controlled incubator 
environment of 5% CO2, 5% O2, and 90% N2, at a temperature of 37
o C (Singh et al., 2007).  
 There are a variety of culture strains that can be chosen to be grown in the 
laboratory. The strains used in this experiment are the D6 and W2 strains. The D6 P. 
falciparum strain originates from Sierra Leone and is effectively utilized as a baseline 
because it has no known drug resistance (Fidock, 2004). The W2 P. falciparum strain has 
its origins in Indochina and is resistant to Chloriquine (CQ), Quinine (QN), Pyrimethamine 
(PYR), Sulfadoxine (SDX), and Cycloguanil (CYC), making it an important strain in 
12 
 
 
 
showing the effectiveness of a new drug in comparison to a drug that has evolved resistance 
(Fidock, 2004).  
 Once a sufficient amount of culture has been grown, the culture can be combined 
with varying drugs and concentrations in a 96-well plate in order to test the antiparasitic 
activity of the drugs in question (Sahu et al.,, 2014). The results of these assays can be 
measured by a variety of methods. Some of the major methods of analysis are: Light 
microscopy with Geimsa staining, Plasmodium LDH assay, SYBR green assay, and 
analysis by flow cytometry. These methods all measure the percent growth of the parasite 
with reference to the control wells and can be analyzed to obtain IC-50 and IC-90 values 
for the drugs used in the experiment. Some advantages of this model are: the ability to 
screen many compounds without the use of animals or humans, the ability to better control 
concentrations and utilize drug combination studies, better discernment for effects like 
addition, antagonism and synergism, and it is lesss expensive than other models. However, 
the physiological effects of a drug cannot be observed in an in vitro study, and having a 
nonliving model allows a drug that could be potentially toxic to animals to eliminate the 
parasite creating a type of false positive test result.  
1.6.2.2 In vivo Rodent Malaria Model 
 Animal models are a vital intermediate between in vitro drug discovery assays and 
human clinical trials. Unlike in vitro trials, animal models allow researchers to observe 
both the anti-parasitic, as well as the biological and physiological effects of a drug. These 
models also provide a more accurate picture of the interaction of the drug with the real 
disease because it is able to progress through its natural host life-cycle and the host-immune 
defenses are present to assist with parasite clearance. The most common in vivo 
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antimalarial model is the mouse model. This is mainly due the availability of laboratory 
mice, the minimal dosing of drug required and relatively low cost compared to other 
screening models. There are currently four Plasmodium species that can be utilized in 
rodent models: P. berghei, P. yoelli, P. chabuadi,  and P. vinckei (Fidock, 2004). 
1.6.2.3 Combination Screening Assays 
 Pursuing the discovery of new antimalarial combination therapies is an important 
part in the worldwide battle against malaria. Combination therapies are able to increase 
efficacy, decrease time of treatment required, and decrease risk of resistance arising in 
the parasite (Kakkilaya, 2015). The most common form of combination therapies is the 
artemisinin-based combination therapies (ACT’s). These therapies showed good results 
in the field, however a few incidences of resistance are being reported leading researchers 
to seek out new combination therapies for the future.  
 The discovery of new combinations is similar in practice to the screening methods 
used in discovering isolated drug therapies, but instead of testing one drug at various 
concentrations, drugs are tested in combination with each other in various concentrations 
in a “checkerboard” format as discussed more thoroughly in the Materials and Methods 
section.  
  
14 
 
 
 
1.7  Objective and hypothesis  
Aretemisnin combination therapies (ACTs) form the first line of treatment for 
complicated as well noncomplicated malaria. Recent studies have shown that efficacy of 
artemisinin may be improved with formation of artemisinin dimers.   Artemisinin dimer 
oxime (DIOX)  (Figure 4) was  recently identified as a promising new antimalarial drug 
lead (ElSohly et al., 2018). In this experimental antimalarial drug the artemisinin molecules 
are  linked by a polyethylene glycol spacer.  The DIOX shown good activity against CQ-
susceptible and CQ resistant strains of P. falciparum, lower IC50 values in vitro when 
compared to artemisinin and also cured the disease in  Plasmodium berghei- mouse malaria 
model. ACTs are not active against the liver stage malaria and also not effective against 
the malaria gametocytes, which are responsible for initiation of infection and transmission 
malaria respectively. NPC1161B, an 8-aminoquinoline (analog of primaquine) antimalarial 
(Figure 4)  is currently under preclinical development. NPC1161B is a single R (-) 
enantiomer developed by the researchers at the NCNPR. NPC1161B is currently under 
late-stage preclinical development. In preclinical studies in animal models NPC1161B has 
shown better therapeutic profile compered to primaquine (which in clinical use) and also 
tafenoquine (which is under clinical development)  
Hypothesis- The new experimental drugs act in combination with the established clinical 
antimalarial drugs and show better antimalarial efficacy. These new combinations are also 
active against drug-resistant isolates of the malaria. DIOX and NPC1161B (the 
experimental antimalarial drugs) were tested in combination with chloroquine and 
artemisnin (the most prominently used antimalarial drugs used in clinics).      
  
15 
 
 
 
Chapter II Materials and Methods 
2.1 Test drugs and compounds 
 Chloroquine (CQ) and artemisinin (ART) were used as the standard antimalarial 
drugs in this study (Figure 4). NPC1161B, an 8-aminoquinoline analog developed by the 
researchers at the NCNPR, which is currently under late stage preclinical development 
(Tekwani and Walker, 2006) was tested as an experimental drug. Recent studies at the 
NCNPR have also identified some new orally active artemisinin dimer antimalarials 
(Elsohly et al., 2017). The artemisinin dimer oxime (DIOX) from this series was tested as 
another experimental antimalarial drug. 
Figure 4: Standard and experimental antimalarial drugs tested as new antimalarial drug 
combinations.    
 
CHLOROQUINE	
ARTEMISININ	
NPC1161B	
ARTEMISININ	DIMER	OXIME	
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2.2 Cell Culture 
 The Plasmodium falciparum laboratory strains of CQ-sensitive D-6  and -resistant 
W-2 were obtained from the Malaria Research and Reference Reagent Resource Center 
(MR4 now BEI Resources- www.beiresources.org) in the United States. P. falciparum 
(strain D6) was originally collected in the Sierra Leone and is generally considered drug-
sensitive. P. falciparum (strain W2) was cloned from the Indochina III/CDC isolate 
originally derived from a Laotian patient who failed chloroquine therapy. The strain W2 is 
reported to be resistant to chloroquine and susceptible to mefloquine. These P. falciparum 
strains were grown in a culture of A+ human red blood cells obtained from the Mississippi 
Blood Services. The culture was maintained at a level of 5% hematocrit in complete 
malaria culture medium (RPMI 1640 with 60 µg/mL of amikacin, 2.2 g of sodium 
bicarbonate per liter of medium, 25 mM HPES buffer). The medium was replaced every 
48 hours and the culture flasks were kept in an incubator environment of 37o C and 
maintained gaseous environment of 90% N2, 5% CO2, and 5% O2.  
2.3 Microscope Parasitemia Analysis 
 Throughout the process of maintenance the level of parasitemia exhibited by the P. 
falciparum cultures was monitored by light microscopy. When the medium was changed, 
blood smears from both the cultures of D-6 and W-2 strains were prepared for analysis. 
The slides were fixed in pure methanol for 30 seconds before being stained with Giemsa 
stain for 50 minutes. After the staining was complete, the slides were washed with distilled 
water and allowed to air dry. Sample images from these slides are presented below in 
Figure 5. 
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Figure 5: Sample slides of Geimsa stained P. falciparum culture (Top). From left to 
right: ring stage, trophozoite, schizont and gametocyte (Bottom). The images taken from 
the Geimsa stained smears of the P. falciparum cultures maintained at our lab.  
 
 The parasitemia analysis was conducted using NIS-Elements software to collect 
pictures from a Nikon Eclipse 90i light microscope equipped with Nikon Digital Sight 
cameras. ImageJ software was then used to count the total number and infected number of 
RBC’s in order to calculate parasitemia. The total RBC count was taken by selecting; 
“binary”, “fill holes”, and “watershed”, and then selecting “analyze particles” (Circularity 
0.25-1.00, Pixels 500-infinity, display outlines). The infected RBC’s in the ring stage only 
were then counted and divided by the total number of RBC’s and multiplied by 100 to 
calculate the culture parasitemia. Before beginning the SYBR Green antimalarial assay, 
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the parasitemia was also counted to calculate the necessary dilution to use to achieve 2% 
parasitemia in 2% hematocrit for the SYBR Green assay. 
 
2.4 Antimalarial SYBR Green I-based fluorescence assay 
 The antimalarial SYBR Green I-based fluorescence assay was used to determine 
the parasite’s response to both the single drug treatment experiments and the combination 
study of drugs (Johnson et al., 2007). This technique utilizes a fluorescent staining 
technique and a plate reader to determine the percent growth of the parasite in response to 
various drug treatments.  
For the single treatment study, the ring stages of the D6 and W2 parasites were 
counted and the parasitemia was adjusted to 2% in 2% hematocrit. Stock solution of the 
drugs and test compounds were prepared in DMSO or deionized water. Each test 
compound was serially diluted in serum-free RMPI medium at eight experimental 
concentrations. The maximum concentrations for the CQ, ART, DIOX, and NPC were 500 
nM, 250 nM, 100 nM, and 5000 nM respectively. The template for this test is presented in 
Table 1 below. After initial setup, the treatment plates were incubated at the culture’s 
standard conditions of 37o C, with 90% N2, 5% CO2, and 5% O2 for 72 hours. Each well 
was then treated with SYBR Green and an RBC lysis buffer before being covered with the 
aluminum foil for compete darkness and placed on a shaker for 1 hour at room temperature. 
The fluorescence of each well was analyzed by the Fluostar Galaxy microplate reader at 
an excitation wavelength of 485 nm and an emission wavelength of 535 nm at 20% gain. 
The gain adjustment determines sensitivity of the fluorescence measurement, which was 
standardized in the initial assays.  
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For the combination assays, the culture was maintained and prepared in identical 
manner to the single treatment experiment. However, instead of performing a serial dilution 
for each drug, a checkerboard assay was set up to test the percent growth of the P. 
falciparum in response to two drugs at varying concentrations. The following four 
combinations were tested: Chloroquine (CQ) with Dimer Oxime (DIOX), Artemisinin 
(ART) with DIOX, CQ with NPC1161B (NPC), and ART with NPC1161B. The maximum 
concentration for CQ, DIOX, and ART was 200 nM, and the maximum concentration used 
for NPC1161B was 5,000 nM. An example template for the combination plate of CQ and 
DIOX is presented in Table 2 below. After the initial setup of the plates, the combination 
assay was performed in the same manner as the single treatment assay described above. 
The percent growth was also analyzed using Xlfit© and the data was represented as IC-50 
values.  
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2.5 Analysis of Data 
 The raw data from the plate reader was collected and the percent growth was 
calculated by comparing the fluorescence values of the treatment wells to the value of the 
control wells. The percent growth and corresponding concentration were paired and 
graphed using Xlfit© software on Excel. This calculation provided IC-50 values with 
standard deviation and presented the data in a growth response curve. P values were 
calculated from the IC-50 values of the combination treatment using the following formula: 
𝑧 =  
𝑎−𝑏
√𝑎+𝑏
  where: z > 1.96 = P < 0.05 
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Chapter III: Results and Conclusion 
 
3.1 Single Drug Treatment  
The activity of each drug, CQ, ART, DIOX, and NPC, was analyzed at varying 
concentrations to obtain an IC-50 value. Because the experiment was run in duplicate, the 
IC-50 values presented in Table 3 below represent the mean IC-50 value obtained from the 
two trials.  
The IC50 values recorded were as follows: For D6 CQ was 26.9 nM, ART was 70.1 
nM, DIOX was 48.5 nM, and NPC was 1297.5 nM. For the W2 strain, the average IC-50 
values were: CQ 355.2, ART 99.9, DIOX 77.4, and NPC 4573.8. The results are presented 
in Table 3 below and recorded as a growth response curves in Figure 6 and Figure 7 below. 
The results confirm CQ-resistant property of the Pf W2 strain.   
 
Table 3: IC-50 values of standard and experimental antimalarial drugs on CQ-susceptible 
(D6) and -resistant (W2) P. falciparum. Values are mean ±SD of four observations  
  
  
Drug 
D6 
IC-50 (nM) 
W2 
IC-50 (nM) 
Chloroquine 26.9 ± 3.8 355.2 ± 37.4 
Artemisinin 70.1 ± 1.6 99.9 ± 16.0 
Dimer Oxime 48.5 ± 0.1 77.4 ± 12.4 
NPC 1161B 1297.5 ± 142.3 626.8 ± 38.3 
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Figure 7: Growth response curve of W2 to CQ, ART, DIOX, and NPC represented in nM 
Figure 6: Growth response curves of D6 to CQ, ART, DIOX, and NPC represented in nM. 
25 
 
 
 
3.2 Combination Assay Results 
 In order to assess the antimalarial activity of the drugs in combination, the SYBR 
Green based fluorescence assay was incorporated with a checkerboard assay of the drugs 
and IC-50 values calculated based on the percent growth observed from the assay.  
 The first combination assessed was Artemisinin with Dimer Oxime. The IC-50 
recorded for the ART only column was 63.1 nM. ART was combined with DIOX over a 
range from 200 nM to 3.125 nM. The effects of DIOX on ART were seen starting at a 
DIOX concentration of 25 nM. At ART + 25 nM DIOX, the IC-50 value was 16.5 nM 
(P<0.05), ART + 12.5 nM DIOX showed an IC-50 was 41.2 (P<0.05), and at ART + 3.125 
nM DIOX the IC-50 was 38.5 (P<0.05). 
 The isolated DIOX column showed an IC-50 value of 32.32 nM. The effects of 
ART on DIOX were evident starting at DIOX + 12.5 nM ART where the IC-50 was 68.544 
nM (P<0.05), a nearly two times increase in IC-50. The results of this combination are 
presented in Table 4, and Figure 8 below.  
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Table 4: The calculated IC-50 values recorded from the combination plate of the drugs 
Artemisinin and Dimer Oxime. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Combination IC-50 (nM) Combination IC-50 (nM) 
ART 63.1 DIOX 
 
32.3 
ART + DIOX 200 <3.125 DIOX+ART 200 
 
<3.125 
ART + DIOX 100 <3.125 DIOX+ART 100 <3.125 
ART + DIOX 50 <3.125 DIOX+ART 50 <3.125 
ART + DIOX 25 16.5 (P<0.05) DIOX+ART 25 20.2 
ART + DIOX 12.5 41.2 (P<0.05) DIOX+ART 12.5 68.5 (P<0.05) 
ART + DIOX 6.25 69.6  DIOX+ART 6.25 73.4 (P<0.05) 
ART + DIOX 3.125 38.5 (P<0.05) DIOX+ART3.125 44.3 (P<0.05) 
Figure 8: The growth response curves (percent growth vs. concentration) of ART in 
combination with DIOX (Top) and DIOX in combination with ART (Bottom). 
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The next combination assessed was with the drugs Artemisinin and NPC 1161B. 
The IC-50 recorded for the isolated ART column was 48.7 nM. ART was combined with 
NPC over a range from 5,000 nM to 78.125 nM. The effects of NPC on ART were seen 
starting at a NPC concentration of 1250 nM. At ART + 1250 nM NPC, the IC-50 value 
was 17.5 nM (P<0.05) and at ART + 312.5 nM NPC, the IC-50 was 18.9 (P<0.05). There 
was no statistically significant difference in IC-50 below this concentration.  
 The isolated NPC column provided an IC-50 value of 671.0 nM. The effects of 
ART on NPC were seen starting at NPC + 1035.2 nM ART through NPC + 3.125 nM ART. 
The recorded IC-50’s of these four combinations were 1035.2 nM, 1352.7 nM, 1588.5 nM, 
and 1890.3 nM respectively (all P<0.05). These results also showed a nearly two-fold 
increase from the isolated IC-50 value of NPC. The results of this combination are 
presented in Table 5, and Figure 9 below.  
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Figure 9: The growth response curves (percent growth vs. concentration) of ART in 
combination with NPC (Top) and NPC in combination with ART (bottom). 
Table 5: This table represents the calculated IC-50 values recorded from the combination 
plate of the drugs Artemisinin and NPC 1161B. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Combination IC-50 (nM) Combination IC-50  (nM) 
ART 48.7 NPC 
 
671.0 
ART + NPC 5000 <3.125 NPC +ART 200 
 
<78.125 
ART +  NPC 2500 <3.125 NPC +ART 100 <78.125 
ART +  NPC 1250 17.5 (P<0.05) NPC +ART 50 <78.125 
ART +  NPC 625 18.9 (P<0.05) NPC +ART 25 1035.2 (P<0.05) 
ART +  NPC 312.5 41.3 NPC +ART 12.5 1352.7 (P<0.05) 
ART +  NPC 156.25 48.5 NPC +ART 6.25 1588.4 (P<0.05) 
ART +  NPC 78.125 45.6 NPC +ART3.125 1890.3 (P<0.05) 
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The next combination assessed was with the drugs Chloroquine and Dimer Oxime. 
The IC-50 recorded for the isolated CQ column was >200 nM because a higher 
concentration of CQ was needed (see discussion).  
 The isolated Dimer Oxime column provided an IC-50 value of 29.0 nM. The effects 
of CQ on DIOX were seen for every concentration combination with each IC-50 recorded 
nearly double that of the isolated value of DIOX (all P<0.05). The results of this 
combination are presented in Table 6, and Figure 10 below.  
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Table 6: This table represents the calculated IC-50 values recorded from the combination 
plate of the drugs Chloroquine and Dimer Oxime. 
 
 
  
 
 
 
 
 
 
 
 
  
Combination IC-50 (nM) Combination IC-50 ( nM ) 
CQ >200 DIOX 
 
29.0 
CQ+ DIOX 200 <3.125 DIOX+ CQ 200 
 
47.7 (P<0.05) 
CQ+ DIOX 100 <3.125 DIOX+ CQ 100 52.5 (P<0.05) 
CQ+ DIOX 50 >200 DIOX+ CQ  50 59.9 (P<0.05) 
CQ+ DIOX 25 >200 DIOX+ CQ 25 56.8 (P<0.05) 
CQ+ DIOX 12.5 >200 DIOX+ CQ 12.5 55.5 (P<0.05) 
CQ+ DIOX 6.25 >200 DIOX+ CQ  6.25 55.5 (P<0.05) 
CQ+ DIOX 3.125 >200 DIOX+ CQ 3.125 51.4 (P<0.05) 
 Figure 10: The growth response curves (percent growth vs. concentration) of DIOX in 
combination with CQ. 
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The final combination assessed was with the drugs Chloroquine and NPC 1161B. 
The IC-50 recorded for the isolated CQ column was 374.0 nM. CQ was combined with 
NPC over a range from 5,000 nM to 78.125 nM. The effects of NPC on CQ were seen at 
the combination of CQ + NPC 1250 where the IC-50 was 150.5 (P<0.05), and at the CQ + 
NPC 625 where the IC-50 was 456.3 (P<0.05). The remaining combinations showed no 
statistically significant results.  
 The isolated NPC column provided an IC-50 value of 607.5 nM. The effects of CQ 
on NPC were seen at every concentration except for NPC + CQ 200. The remaining CQ 
concentration combinations showed a nearly threefold increase in IC-50 value (all P<0.05). 
The results of this combination are presented in Table 7 and Figure 11 below.  
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Figure 11: The growth response curves (percent growth vs. concentration) of CQ in 
combination with NPC (Top) and NPC in combination with CQ (bottom). 
 
Table 7: This table represents the calculated IC-50 values recorded from the combination 
plate of the drugs Chloroquine and NCP 1161B 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Combination IC-50 (nM Combination IC-50 (nM) 
CQ 374.0 NPC 607.5 
CQ + NPC 5000 <6.25 NPC + CQ 200 <78.125 
CQ + NPC 2500 <6.25 NPC + CQ 100 1616.9 (P<0.05) 
CQ + NPC 1250 150.5 (P<0.05) NPC + CQ 50 1594.5 (P<0.05) 
CQ + NPC 625 456.3 (P<0.05) NPC + CQ 25 1308.4 (P<0.05) 
CQ + NPC 312.5 379.9 NPC + CQ 12.5 1653.8 (P<0.05) 
CQ +  NPC 156.25 380.8 NPC + CQ 6.25 1767.1 (P<0.05) 
CQ + NPC 78.125 386.4 NPC + CQ 3.125 1367.1 (P<0.05) 
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3.3 Conclusions 
 The results of the single treatment control assay helped to establish the drug 
resistant nature of the W2 strain of P. falciparum. The IC-50 value of CQ in the W2 strain 
increased from 26.9 nM in the D6 treatment to 355.2 nM in the W2 treatment. This 
significant increase in IC-50 value across strains confirms the CQ resistant nature of the 
W2 laboratory strain of P. falciparum .   
The IC-50 of the ART + DIOX 25 nM treatment showed a statistically significant 
decrease in IC-50 value from 63.1 nM to 16.5 nM. This suggests that DIOX could be 
showing additive effects to the activity of ART in vitro. However, the effects of ART on 
the activity of DIOX suggest that partial antagonism has occurred. At DIOX + ART 25 nM 
and 12.5 nM, the IC-50 value is more than twice the value of the control DIOX IC-50 of 
32.3 nM suggesting ART enacts partial antagonism on the activity of DIOX. 
For the combination of ART and NPC, the IC-50 showed a statistically significant 
decrease from the control ART IC-50 value of 48.7 nM at the treatment group of ART + 
NPC 1250 nM and 625 nM. This decrease in IC-50 value suggests that NPC shows partial 
additive effects on the activity of ART. The effects of ART on NPC showed a nearly two-
fold increase in IC-50 value when compared to the NPC control IC-50 value of 671.0 nM. 
This two fold, and in the case of NPC + ART 3.125 nM three-fold, increase in IC-50 value 
suggest that ART shows partial antagonism on the activity of NPC in vitro.  
A mistake was made in the experimental setup with regard to the CQ and DIOX 
combination. Because of the CQ resistant nature of the W2 strain of P. falciparum, a higher 
concentration of CQ should have been used in order to obtain an IC-50 value for the 
experiment. However, while the concentration of CQ was low, the DIOX + CQ 
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combination showed a statistically significant increase in IC-50 value at all experimental 
concentration combinations. 
For the combination of NPC + CQ, the IC-50 showed a statistically significant 
increase from the NPC control IC-50 of 607.5 nM for all concentrations except that of NPC 
+ CQ 200 nM where the concentration of CQ was sufficient to kill the parasite. The two to 
three-fold increase in IC-50 values recorded suggests that CQ shows partial antagonism on 
the activity of NPC in vitro.  
These results are the first from the lab to be reported on these drug combinations. 
It appears from the data that CQ and ART both antagonize the activity of NPC 1161B, 
however repeated studies and further evaluation need to be conducted to confirm the 
results. Overall the results from the single treatment test suggest that both Dimer Oxime 
and NPC 1161B could be effective clinical antimalarials. However, the results from the 
combination assays suggest that they both have the potential to show antagonism in 
combination with other drugs. These results should be tested again in vitro in order to be 
confirmed, and if confirmed, should then be continued to be evaluated in the mouse model 
to further analyze the activity.  
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